news
Amgen and Astellas Pharma US agree to settlement costs for kickback charges
Amgen and Astellas Pharma US have agreed to pay a total of $124.75 million to settle allegations that they paid kickbacks to Medicare copays for their own medications.
List view / Grid view
Kyprolis (carfilzomib)
news
Amgen submits sNDA for Kyprolis in relapsed multiple myeloma
23 July 2015 | By Victoria White
Amgen has submitted a sNDA to the US FDA for Kyprolis to seek an expanded indication for the treatment of patients with relapsed multiple myeloma...
news
FDA grants Amgen priority review for Kyprolis for the treatment of relapsed multiple myeloma
31 March 2015 | By Victoria White
Amgen has announced that the FDA has accepted the sNDA of Kyprolis for the treatment of patients with relapsed multiple myeloma...
news
Phase 3 head-to-head ENDEAVOR study demonstrates superiority of Kyprolis® (carfilzomib) over Velcade® (bortezomib) in patients with relapsed multiple myeloma
2 March 2015 | By Amgen
Study met primary endpoint of progression-free survival patients receiving Kyprolis lived twice as long without disease progression...
news
Amgen announces top-line results from Phase 3 focus trial of kyprolis® in patients with relapsed and advanced refractory multiple myeloma
15 August 2014 | By Amgen
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival...
news
Amgen announces Phase 3 ASPIRE trial of Kyprolis® in patients with relapsed multiple myeloma met primary endpoint
4 August 2014 | By Amgen
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival...
news
Amgen and Onyx Data at ASCO 2014 highlight oncology pipeline and portfolio
28 May 2014 | By Amgen
New data reinforces commitment to personalized medicine and highlights advances in immunotherapy platform...
